Substituted heterocycles for targeting HSP90
Described herein are substituted indazoles comprising formula (II) that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. Formula (II) may link to detection moieties such as fluorophores that may allow for selective detection of Hsp90 in a sample.
1. A compound of formula (I):
wherein:
A is a heat shock protein 90 binding component of formula (II):
wherein:
R 1 is —H or —C 1-8 -alkyl;
R 2 is —H or —C 1-8 -alkyl;
R 3 is —H, —F or —OCH 3 ;
R 4 is —H, —F or —OCH 3 ;
R 5 is —H, —F or —OCH 3 ;
R 6 is —C 1-8 -alkyl, —C 2-8 -alkenyl, —C 2-8 -alkynyl, —C 3-8 -cycloalkenyl, —C 3-8 -cycloalkenyl-C 1-8 -alkyl, —C 3-8 -cycloalkyl, —C 3-8 -cycloalkyl-C 1-8 -alkyl, aryl, aryl-C 1-8 -alkyl, halo-C 1-8 -alkyl, heteroaryl, heteroaryl-C 1-8 -alkyl, heterocyclyl, heterocyclyl-C 1-8 -alkyl or hydroxy-C 1-8 -alkyl;
R 7 is —H or —C 1-8 -alkyl;
R 8 is —H or —C 1-8 -alkyl; or
R 7 and R 8 , taken together with the carbon atom to which they are attached, form a —C 3-8 -cycloalkyl;
R 9 is —H or —C 1-8 -alkyl;
X is —CR 9 or —N;
Y is —CR 3 or —N; and
is the point of attachment in formula (I);
X 1 is —NH—, —O—, —S—, —C(O)— or —S(O) 2 ;
L is a divalent linker of the following formula:
—(CH 2 ) m —(OCH 2 CH 2 ) n —O—(CH 2 ) p —,
wherein:
m is 2 or 3;
n is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; and
p is 2 or 3;
X 2 is —NR—, —O—, —S—, —C(O)— or —S(O) 2 ;
R is —H or a detection moiety; and
B is an anti-cancer agent comprising ferrocene;
wherein the detection moiety comprises a fluorophore or a radioactive compound;
wherein the fluorophore is a fluorescein, a rhodamine, a coumarin, a cyanine or a boron-dipyrromethene;
wherein the radioactive compound is a radioisotope; and
wherein the anti-cancer agent is an alkylating agent, an anti-epidermal growth factor receptor antibody, an anti-Her-2 antibody, an antimetabolite, a vinca alkaloid, an anthracycline, a platinum-based agent, a topoisomerase inhibitor, a taxane, an anti-cancer antibiotic, an immune cell antibody, an interferon, an interleukin, a heat shock protein 90 inhibitor, an anti-androgen, an anti-estrogen, an antihypercalcemia agent, an apoptosis inducer, an aurora kinase inhibitor, a Bruton's tyrosine kinase inhibitor, a calcineurin inhibitor, a Ca 2+ -calmodulin-dependent protein kinase II inhibitor, a CD45 tyrosine phosphatase inhibitor, a cell division cycle 25 phosphatase inhibitor, a checkpoint kinase inhibitor, a cyclooxygenase inhibitor, a cRAF kinase inhibitor, a cyclin dependent kinase inhibitor, a cysteine protease inhibitor, a deoxyribonucleic acid intercalator, a deoxyribonucleic acid strand breaker, an E3 ligase inhibitor, an epidermal growth factor pathway inhibitor, a farnesyltransferase inhibitor, a fetal liver kinase-1 inhibitor, a glycogen synthase kinase-3 inhibitor, a histone deacetylase inhibitor, an I-kappa B-alpha kinase inhibitor, an imidazotetrazinone, an insulin tyrosine kinase inhibitor, a c-Jun N-terminal kinase inhibitor, a mitogen-activated protein kinase inhibitor, a mouse double minute 2 inhibitor, an MEK inhibitor, a matrix metalloproteinase inhibitor, a mammalian target of rapamycin inhibitor, a nerve growth factor receptor tyrosine kinase inhibitor, a p38 mitogen-activated protein kinase inhibitor, a p56 tyrosine kinase inhibitor, a platelet-derived growth factor pathway inhibitor, a phosphatidylinositol 3-kinase inhibitor, a phosphatase inhibitor, a protein phosphatase inhibitor, a protein kinase C inhibitor, a protein kinase C delta kinase inhibitor, a polyamine synthesis inhibitor, a protein tyrosine phosphatase 1B inhibitor, a protein tyrosine kinase inhibitor, an SRC family tyrosine kinase inhibitor, a spleen tyrosine kinase inhibitor, a Janus tyrosine kinase inhibitor, a retinoid, a ribonucleic acid polymerase II elongation inhibitor, a serine/threonine kinase inhibitor, a sterol biosynthesis inhibitor, a vascular endothelial growth factor pathway inhibitor, alitretinon, altretamine, aminopterin, aminolevulinic acid, amsacrine, asparaginase, atrasentan, bexarotene, carboquone, demecolcine, efaproxiral, elsamitrucin, etoglucid, a Gliadel implant, hydroxycarbamide, leucovorin, lonidamine, lucanthone, masoprocol, methyl aminolevulinate, mitoguazone, mitotane, oblimersen, omacetaxine, pegaspargase, porfimer sodium, prednimustine, sitimagene ceradenovec, talaporfin, temoporfin, trabectedin or verteporfin.
2. The compound of claim 1 , wherein:
R 1 is —H;
R 2 is —H;
R 3 is —H;
R 4 is —H;
R 5 is —H;
R 6 is —C 1-8 -alkyl or halo-C 1-8 -alkyl;
R 7 is —C 1-8 -alkyl;
R 8 is —C 1-8 -alkyl;
X is —N; and
Y is —CR 3 .
3. The compound of claim 1 , wherein A has the following formula:
4. The compound of claim 2 , wherein B is —CH 2 -ferrocenyl.
5. The compound of claim 4 , wherein X 1 is —NH— and X 2 is —NH—.
6. The compound of claim 5 , wherein n is 4.
7. The compound of claim 6 , wherein m is 3 and p is 3.
8. The compound of claim 1 , wherein B is —CH 2 -ferrocenyl.
9. The compound of claim 1 , wherein X 1 is —NH— and X 2 is —NH—.
10. The compound of claim 1 , wherein n is 4.
11. The compound of claim 1 , wherein m is 3 and p is 3.
12. The compound of claim 1 , wherein the compound is:
13. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
14. A kit comprising a compound of claim 1 .
15. A method for detecting heat shock protein 90 in a sample, wherein the method comprises the following steps:
a) contacting the sample with the compound of claim 1 , wherein R is a detection moiety; and
b) detecting a signal from the detection moiety.
16. A method for detecting cancer in a subject, wherein the method comprises the following steps:
a) contacting a biological sample from the subject with the compound of claim 1 , wherein R is a detection moiety; and
b) detecting a signal from the detection moiety.
17. The method of claim 16 , wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, non-small cell lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer and melanoma.
18. A method for treating cancer in a subject, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1 .
19. The method of claim 18 , wherein the subject has a cancer selected from the group consisting of breast cancer, prostate cancer, non-small cell lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer and melanoma.
20. A compound, wherein the compound is: